In estrogen receptor (ER) positive breast cancers, accounting for 80% of all breast cancers, Her3 is mutated in up to 14% and its upregulation appears to be responsible for neuregulin-mediated resistance to Fulvestrant, an ER downregulator [37,38,39]. The gene discussed is ERBB3; the disease is breast carcinoma.